Lineage reports Q2 net loss of $6.8M ($0.04/sh); cash $72M supports through Q2 2024

Lineage Cell Therapeutics, Inc.

2022-Q2 EPS reported -$0.08 revenue$9,790,000

Revenue $4.6M, up $4.0M YoY, primarily from Roche collaboration licensing fee.
Net loss attributable to Lineage $6.8M ($0.04/sh) vs $4.8M ($0.03/sh) in Q2 2021.
R&D expenses $3.3M; G&A $5.3M; total operating expenses $8.6M.
Cash, equivalents, and marketable securities $72M; funds operations through Q2 2024.
OpRegen collaboration with Roche advancing; OPC1 results published in J Neurosurg; VAC2 tech transfer complete.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.